GLI2 and acute myeloid leukemia: Further work has found that primary AML cells from some patients with high GLI1 expression will have reduced proliferation and self-renewal capacity when treated with the GLI1 and GLI2 inhibitor GANT61 but not when treated with SMOi (57).